메뉴 건너뛰기




Volumn 84, Issue 4, 2012, Pages 869-870

Top ten clinical research downloads of 2011

(1)  Zietman, Anthony a  

a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; CISPLATIN; PLACEBO; SODIUM CHLORIDE; MONOCLONAL ANTIBODY;

EID: 84872022269     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/S0360-3016(12)03630-9     Document Type: Editorial
Times cited : (8)

References (11)
  • 1
    • 84862646773 scopus 로고    scopus 로고
    • The red journal's top 10 most downloaded articles of 2011
    • Zietman AL. The Red Journal's Top 10 Most Downloaded Articles of 2011. Int J Radiat Oncol Biol Phys. 2012; 83(4):1073-1074.
    • (2012) Int J Radiat Oncol Biol Phys. , vol.83 , Issue.4 , pp. 1073-1074
    • Zietman, A.L.1
  • 2
    • 79959335126 scopus 로고    scopus 로고
    • 70 gy versus 80 gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial
    • Beckendorf V, Guerif S, Le Prisé E, et al. 70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of GETUG 06 Randomized Trial. Int J Radiat Oncol Biol Phys. 2011; 80(4):1056-1063.
    • (2011) Int J Radiat Oncol Biol Phys. , vol.80 , Issue.4 , pp. 1056-1063
    • Beckendorf, V.1    Guerif, S.2    Le Prisé, E.3
  • 3
    • 37049023209 scopus 로고    scopus 로고
    • Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer
    • Kuban DA, Tucker SL, Dong L, et al. Long-Term Results of the M.D. Anderson Randomized Dose-Escalation Trial for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2008; 70(1):67-74.
    • (2008) Int J Radiat Oncol Biol Phys. , vol.70 , Issue.1 , pp. 67-74
    • Kuban, D.A.1    Tucker, S.L.2    Dong, L.3
  • 4
    • 78650804126 scopus 로고    scopus 로고
    • Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy
    • Martinez AA, Gonzalez J, Ye H, et al. Dose Escalation Improves Cancer-Related Events at 10 Years for Intermediate- and High-Risk Prostate Cancer Patients Treated With Hypofractionated High-Dose-Rate Boost and External Beam Radiotherapy. Int J Radiat Oncol Biol Phys. 2011; 79(2):363-370.
    • (2011) Int J Radiat Oncol Biol Phys. , vol.79 , Issue.2 , pp. 363-370
    • Martinez, A.A.1    Gonzalez, J.2    Ye, H.3
  • 5
    • 79954420210 scopus 로고    scopus 로고
    • Image-guided radiotherapy (IGRT) for prostate cancer comparing kV imaging of fiducial markers with cone beam computed tomography
    • Barney BM, Lee RJ, Handrahan D, et al. Image-Guided Radiotherapy (IGRT) for Prostate Cancer Comparing kV Imaging of Fiducial Markers With Cone Beam Computed Tomography. Int J Radiat Oncol Biol Phys. 2011; 80(1):301-305.
    • (2011) Int J Radiat Oncol Biol Phys. , vol.80 , Issue.1 , pp. 301-305
    • Barney, B.M.1    Lee, R.J.2    Handrahan, D.3
  • 6
    • 84855825726 scopus 로고    scopus 로고
    • Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer
    • King CR, Brooks JD, Gill H, et al. Long-Term Outcomes from a Prospective Trial of Stereotactic Body Radiotherapy for Low-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2012; 82(2):877-882.
    • (2012) Int J Radiat Oncol Biol Phys. , vol.82 , Issue.2 , pp. 877-882
    • King, C.R.1    Brooks, J.D.2    Gill, H.3
  • 7
    • 81855203431 scopus 로고    scopus 로고
    • Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: Can SBRT be comparable to surgery?
    • Onishi H, Shirato H, Nagata Y, et al. Stereotactic Body Radiotherapy (SBRT) for Operable Stage I Non-Small-Cell Lung Cancer: Can SBRT Be Comparable to Surgery? Int J Radiat Oncol Biol Phys. 2011; 81(5): 1352-1358.
    • (2011) Int J Radiat Oncol Biol Phys. , vol.81 , Issue.5 , pp. 1352-1358
    • Onishi, H.1    Shirato, H.2    Nagata, Y.3
  • 8
    • 79954414622 scopus 로고    scopus 로고
    • Is radiation indicated in patients with ductal carcinoma in situ and close or positive mastectomy margins?
    • Chan LW, Rabban J, Hwang ES, et al. Is Radiation Indicated in Patients With Ductal Carcinoma In Situ and Close or Positive Mastectomy Margins? Int J Radiat Oncol Biol Phys. 2011; 80(1):25-30.
    • (2011) Int J Radiat Oncol Biol Phys. , vol.80 , Issue.1 , pp. 25-30
    • Chan, L.W.1    Rabban, J.2    Hwang, E.S.3
  • 9
    • 80255134559 scopus 로고    scopus 로고
    • Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer
    • Koutcher L, Sherman E, Fury M, et al. Concurrent Cisplatin and Radiation Versus Cetuximab and Radiation for Locally Advanced Head-and-Neck Cancer. Int J Radiat Oncol Biol Phys. 2011; 81(4): 915-922.
    • (2011) Int J Radiat Oncol Biol Phys. , vol.81 , Issue.4 , pp. 915-922
    • Koutcher, L.1    Sherman, E.2    Fury, M.3
  • 10
    • 18544409287 scopus 로고    scopus 로고
    • A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG9003
    • Fu KK, Pajak TF, Trotti A, et al. A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000; 48(1):7-16.
    • (2000) Int J Radiat Oncol Biol Phys. , vol.48 , Issue.1 , pp. 7-16
    • Fu, K.K.1    Pajak, T.F.2    Trotti, A.3
  • 11
    • 79952698481 scopus 로고    scopus 로고
    • Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system
    • Levin VA, Bidaut L, Hou P, et al. Randomized Double-Blind Placebo-Controlled Trial of Bevacizumab Therapy for Radiation Necrosis of the Central Nervous System. Int J Radiat Oncol Biol Phys. 2011; 79(5):1487-1495.
    • (2011) Int J Radiat Oncol Biol Phys. , vol.79 , Issue.5 , pp. 1487-1495
    • Levin, V.A.1    Bidaut, L.2    Hou, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.